logo
#

Latest news with #QuantumAMC

IT sector poised for earnings surprise in FY26-27 on reviving tech spend: Christy Mathai
IT sector poised for earnings surprise in FY26-27 on reviving tech spend: Christy Mathai

Time of India

time3 days ago

  • Business
  • Time of India

IT sector poised for earnings surprise in FY26-27 on reviving tech spend: Christy Mathai

"Combination of these factors we are fairly positive on the EPS trajectory going ahead and this environment is very good for the private capex to grow as well because you have had interest rate cuts. The corporates can borrow cheaper. At present, they have significant cash on their books. But given the tariff uncertainty especially with respect to Trump and so on and so forth, there is some issues on that front," says Christy Mathai , Quantum AMC. Give us a sense of how you are positioning your portfolio amid all the geopolitical uncertainty we are seeing right now. How much of it is deployed? How much are you sitting in terms of cash? Christy Mathai: So, clearly this economic backdrop is pretty conducive compared to what it was, let us say, about three or six months back. What we have seen is the government is really pushing the pedal on growth and we have some indication of it as we look at the 4Q GDP numbers as well. Also, the inflation is clearly moderating and we do not think the current geopolitical issues would really change that materially unless the crude were to go really up which we do not foresee in a normal case scenario and against this backdrop, what we have seen is RBI is infusing liquidity and frontloaded quite a bit of interest rate cuts, so this should propel some sort of earnings growth going ahead, the CRR cut of 100 basis points was particularly positive, it has a multiplier impact on the economy because the lending increases assuming the bank do not park it in G-Secs and they start lending again. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Kulkas yang belum Terjual dengan Harga Termurah (Lihat harga) Cari Sekarang Undo So, combination of these factors we are fairly positive on the EPS trajectory going ahead and this environment is very good for the private capex to grow as well because you have had interest rate cuts. The corporates can borrow cheaper. At present, they have significant cash on their books. But given the tariff uncertainty especially with respect to Trump and so on and so forth, there is some issues on that front. But broadly, we think all the signs are right for the earnings growth to slowly pick up. Our concerns chiefly is on the valuations, given the 10% or more rally that we have seen in the past couple of months, valuation is the only concern for us and hence possibly, we are not looking at a great set of returns one-year or two-year out. But apart from that broadly earnings trajectory should be positive. Live Events But any new sector where you believe the earnings momentum can really take the sector higher from the current levels because a lot of sector churning is already underway. We have seen the runup in financials. Other than that, of late, it is the IT, select healthcare counters that are making a comeback. Christy Mathai: So, in terms of earnings, possibly where things can look up from our sense is purely looking at the IT pack. We have had possibly very near-term rally, so to say in it, but what we are looking at is most of the FY26 numbers have been dramatically cut, it is possibly in the vicinity of maybe 3% to 5% growth which possibly the managements are guiding, but we think this number at least maybe FY26-27 could be much better owing to the fact that the technology spends possibly can come back because we are sitting over a three years of absolutely no IT spends especially on the services part by the major banks in US or manufacturing sector. So, there is a possibility of that picking up, plus the margins also can expand given some of the cost levers that most of the IT players have in hand. So, we think you that could be a possible place where there could be earnings surprise as we move ahead. But broadly, if you were to just think about the consumption theme also, where we are invested through autos primarily which is also a play on interest rate cut and there could be better credit growth in that particular sector, which is at present not happening, so some of these two-wheeler volumes especially in the mass segment which have been hit by inflation for a long time which is now moderating can be a surprise going ahead. While we are talking about consumption, let us talk about an ancillary that is cement in a way. Give us a sense on where you are seeing cement as a sector moving ahead because we have seen benign raw material on the other hand, you have the monsoon overhang, so that seasonality is coming into play. Where do you see the cement sector headed now? Christy Mathai: So, we are invested in cement sector as a whole through one of the companies which is more contained to a specific geographic location where the price hike in the recent past has been good. But see over the course of the year you will have a usual seasonality play out, typically monsoon season you will see some demand moderation which picks up as you go ahead in the month of October or towards the Diwali, so that is the usual seasonality. The issue last year was one of a kind because you have had significant demand moderation along with fierce competitiveness because a lot of large players who have sort of consolidated were pushing up the volumes in through some of their acquired entities, so that was what is depressing the prices to a four-year or five-year low. Now, we see that improving which is sort of a big positive for the sector as a whole. Monsoon seasonality, it usually happens, so there is nothing concerning as such and the government capex and slowly the demand recovery in, let us say, the housing segment should be a key driver as you look at the cement stocks. We did touch upon select sectors there and also you did share your outlook on the earnings front, but if I have to ask you top three sectors where you are most bullish on which one those will be and the three sectors you believe will be languishing for some time from now to participate in the rally for Indian markets. Christy Mathai: So, clearly where we have large allocation are clearly the banks, financials which is not very different from when you look at an index perspective. But the point is here we think until now if you were to look at the whole people visualising the rate cut cycle, they were expecting an extended rate cut cycle, but with the stance change and the commentary that you hear looks like there will not be further rate cuts so what you will have there is a one or two, maybe three quarter impact on NIMs, but CRR cut is positive, so that is on the extreme near term in terms of what will happen. But otherwise, we think the credit growth should normalise ahead. IT is at 9%, sub-9% at the moment and the deposit challenges are slowly going away. So, you should see that credit growth pick up as you go through the year, possibly in the second half, so 12-13% is what we think the long-term on credit growth has been for a very long period of time, we do not see that change, and within that the private players would have their play with a slightly higher growth rates, so that remains a pocket which is very attractive to us and reasonably valued in our view. The other sector as I said was it and some bit in consumption which is especially the auto pack with primarily play on two wheelers, so that is broadly our sectors where we are reasonably positive on. We have picked up on some of the financial plays as well, something like an insurance which we have added in the recent past that also looks pretty attractive when you were to really think about long-term growth because there is significant protection gap as we see it in the life insurance space and the valuations are not so expensive. The pocket where we are not so convinced about is again this is primarily driven by valuations. You just look at some of the cap goods names, some of the names which are driven by order book especially dependent on how the government spend would be, those are the pockets where there could be room for disappointment going ahead in a sense and some of the capital market linked themes where there could be impact in one of these years, we cannot really pinpoint which year it would be. So, these would be places where we would be a little bit wary off, but by and large positive.

Christy Mathai, Fund Manager- Equity, Quantum AMC
Christy Mathai, Fund Manager- Equity, Quantum AMC

Time of India

time6 days ago

  • Business
  • Time of India

Christy Mathai, Fund Manager- Equity, Quantum AMC

Let's start with your personal story How did you land up in this job? Live Events Which funds are you currently managing? What is your investment philosophy and how would you describe your strategy? What motivates you while managing other people's money? I hail from Palakkad in Kerala, but thanks to my parents' postings in the armed forces, I ended up changing schools 6–7 times across the country. While it was challenging at the time, it gave me early exposure to diverse cultures, languages, and people—something I deeply value school, I pursued engineering. A standout experience was my internship with the Mumbai Monorail project—India's first attempt at this form of urban transport. It offered a real-world view of infrastructure planning and execution, and it was here that I first came across financial concepts like project viability and IRR (Internal Rate of Return). Post engineering, I joined TCS and worked at CRL (Computational Research Laboratories), which developed 'EKA'—the 4th fastest supercomputer in the world at the time. It was used by ISRO during the Chandrayaan mission. Working with professionals across fields on cutting-edge applications like weather modelling, drug discovery, and Formula 1 simulations was incredibly this time, I became increasingly curious about what makes companies and management teams succeed. Conversations with colleagues who actively invested in equities pushed me to explore further. I started taking finance courses and enrolled in the CFA program to build a structured strengthen this interest, I pursued an MBA in Finance from IMT Ghaziabad. My internship during the MBA introduced me to value investing through two mentors whose guidance shaped my thinking. That experience was pivotal—and it eventually led me to begin my investing career at internship experience in value investing reaffirmed my desire to pursue investing as a full-time career. Around the same time, I discovered that my father had been a long-term investor with Quantum AMC and appreciated its long-term, disciplined investment approach. I also admired Quantum's thought leaders like Ajit Dayal and I. V. Subramaniam (Subbu).As luck would have it, Quantum Advisors —the parent company of Quantum AMC—was hiring around the time I was completing my MBA. I joined the Emerging Markets (EM) team, where I covered sectors like Indian IT services, Chinese internet, and Asian semiconductors. I had the privilege of being mentored by Aureole Foong and Francisco Alzuru—industry veterans in global value investing. Working with them helped me gain a deeper understanding of how industries evolve across geographies and the importance of global time, I transitioned to tracking additional sectors, constructing portfolios, and eventually began focusing exclusively on the Indian equity market.I currently manage the Quantum Value Fund and the Quantum ELSS Tax Saver the funds follow a disciplined value investing approach—focusing on fundamentally sound companies available at a discount to their intrinsic value. While our Value Fund is a diversified, benchmark-agnostic equity fund, ELSS Tax Saver Fund combines long-term investing with tax-saving benefits under the ELSS investment philosophy is straightforward: we aim to invest in stocks of companies trading at a minimum 25% discount to their fair or intrinsic value. Often, these opportunities arise because the market is fixated on short-term disappointments, while we take a long-term perspective. However, every investment must meet our rigorous filters of corporate governance, liquidity , and estimate fair value, we focus on what we believe are the company's normalised earnings two years ahead. We have a large team covering various sectors and we spend considerable time understanding and analysing that. A visible catalyst—something that can help the stock move toward its intrinsic value—is also a stock approaches its fair value, we may consider trimming or exiting the position, unless there is a material change in its earnings trajectory. As a result, in a bull market, we may end up holding cash because many stocks hit our sell thresholds and there are new ideas to deploy. In a bear market , however, we may be fully portfolio is benchmark-agnostic and has a large-cap tilt due to our liquidity filters. It is a fairly concentrated portfolio with characteristics like valuation, growth, and dividend yield reflecting a clear value bias.A mutual fund is an excellent vehicle to help investors reach their long-term financial goals. Managing other people's money is both a privilege and a responsibility. I see it as stewardship—something that must be approached with care, discipline, and a long-term mindset.

Christy Mathai, Fund Manager- Equity, Quantum AMC
Christy Mathai, Fund Manager- Equity, Quantum AMC

Economic Times

time6 days ago

  • Business
  • Economic Times

Christy Mathai, Fund Manager- Equity, Quantum AMC

I hail from Palakkad in Kerala, but thanks to my parents' postings in the armed forces, I ended up changing schools 6–7 times across the country. While it was challenging at the time, it gave me early exposure to diverse cultures, languages, and people—something I deeply value today. After school, I pursued engineering. A standout experience was my internship with the Mumbai Monorail project—India's first attempt at this form of urban transport. It offered a real-world view of infrastructure planning and execution, and it was here that I first came across financial concepts like project viability and IRR (Internal Rate of Return). Post engineering, I joined TCS and worked at CRL (Computational Research Laboratories), which developed 'EKA'—the 4th fastest supercomputer in the world at the time. It was used by ISRO during the Chandrayaan mission. Working with professionals across fields on cutting-edge applications like weather modelling, drug discovery, and Formula 1 simulations was incredibly formative. During this time, I became increasingly curious about what makes companies and management teams succeed. Conversations with colleagues who actively invested in equities pushed me to explore further. I started taking finance courses and enrolled in the CFA program to build a structured strengthen this interest, I pursued an MBA in Finance from IMT Ghaziabad. My internship during the MBA introduced me to value investing through two mentors whose guidance shaped my thinking. That experience was pivotal—and it eventually led me to begin my investing career at internship experience in value investing reaffirmed my desire to pursue investing as a full-time career. Around the same time, I discovered that my father had been a long-term investor with Quantum AMC and appreciated its long-term, disciplined investment approach. I also admired Quantum's thought leaders like Ajit Dayal and I. V. Subramaniam (Subbu). As luck would have it, Quantum Advisors —the parent company of Quantum AMC—was hiring around the time I was completing my MBA. I joined the Emerging Markets (EM) team, where I covered sectors like Indian IT services, Chinese internet, and Asian semiconductors. I had the privilege of being mentored by Aureole Foong and Francisco Alzuru—industry veterans in global value investing. Working with them helped me gain a deeper understanding of how industries evolve across geographies and the importance of global time, I transitioned to tracking additional sectors, constructing portfolios, and eventually began focusing exclusively on the Indian equity market.I currently manage the Quantum Value Fund and the Quantum ELSS Tax Saver the funds follow a disciplined value investing approach—focusing on fundamentally sound companies available at a discount to their intrinsic value. While our Value Fund is a diversified, benchmark-agnostic equity fund, ELSS Tax Saver Fund combines long-term investing with tax-saving benefits under the ELSS investment philosophy is straightforward: we aim to invest in stocks of companies trading at a minimum 25% discount to their fair or intrinsic value. Often, these opportunities arise because the market is fixated on short-term disappointments, while we take a long-term perspective. However, every investment must meet our rigorous filters of corporate governance, liquidity, and estimate fair value, we focus on what we believe are the company's normalised earnings two years ahead. We have a large team covering various sectors and we spend considerable time understanding and analysing that. A visible catalyst—something that can help the stock move toward its intrinsic value—is also important. Once a stock approaches its fair value, we may consider trimming or exiting the position, unless there is a material change in its earnings trajectory. As a result, in a bull market, we may end up holding cash because many stocks hit our sell thresholds and there are new ideas to deploy. In a bear market, however, we may be fully invested. The portfolio is benchmark-agnostic and has a large-cap tilt due to our liquidity filters. It is a fairly concentrated portfolio with characteristics like valuation, growth, and dividend yield reflecting a clear value bias. A mutual fund is an excellent vehicle to help investors reach their long-term financial goals. Managing other people's money is both a privilege and a responsibility. I see it as stewardship—something that must be approached with care, discipline, and a long-term mindset.

Market recovery driven by easing macros and FII inflows, but valuations remain expensive: Christy Mathai
Market recovery driven by easing macros and FII inflows, but valuations remain expensive: Christy Mathai

Economic Times

time27-05-2025

  • Business
  • Economic Times

Market recovery driven by easing macros and FII inflows, but valuations remain expensive: Christy Mathai

Agencies Are you able to generate a secular 18-20% sort of return on equity, that seems to be the concerns especially considering the valuations that we see. "If you were to look at the earnings trajectory, again first half was pretty bad you have seen sizable earnings cut especially if you were to look at the FY26-27 earnings. But then, this earning season is probably a bit mixed. There are some pockets which have done well, some which has not," says Christy Mathai, Fund Manager-Equity, Quantum AMC. What a move in the markets of late though the news flow was quite volatile. We have been hearing from President Trump. The earning season is in full swing and then, we had the tensions border across. But there is always saying that good price and good news does not come along. Now that we are seeing that the prices are quite looking good, the bulls are seen to be back, especially with their interest in the largecap space and the news is also turning out to be the good, help us understand what is your take on the markets, is the price still good to go ahead and chip in some money? Christy Mathai: So, clearly, as you said the markets have just recovered quite sharply if you were to look at it and possibly some of the easing that we have seen on the macros, especially global macros for that matter, some of the geopolitical tensions easing would have contributed to that and we have seen a fair bit of inflows from the FIIs also, so which has kind of propelled the market to where it is. But see, I would look at from two-three lens. One, of course, if you were to just look at the plain macros, yes, things are improving after sort of not a weak first half FY25, things are just gradually inching up though the GDP estimates has been cut, possibly some bit of easing is happening especially if you look at the RBI actions, there is lot of liquidity infusion, if you were to look at the inflation, things have just kind of come down, that is on the macros. If you were to look at the earnings trajectory, again first half was pretty bad you have seen sizable earnings cut especially if you were to look at the FY26-27 earnings. But then, this earning season is probably a bit mixed. There are some pockets which have done well, some which has not. Our sense is the ask rate in terms of earnings is around 11, 11.5 which is not so demanding. So, the earnings cut further on may not be so steep, perhaps it would have bottomed out in that sense. But the mood point is the valuations. The valuations remain expensive across most of the buckets and that is true more also in the broader end, but if you were to just look out Nifty 50 or BSE 30, the valuations at Nifty at 21.5 is expensive. So, if you were to just put it all together, yes, we are more constructive with the markets, from the levels six to eight months back, but investors have to possibly be looking at moderate returns, especially in the context of what we have seen three- to five-year returns. Now, the kind of recovery that we have seen in the past few days and also the earnings trajectory, just like you were mentioning, are there any particular pockets where you see value in currently and are there any spaces that one must avoid at this point in time? Christy Mathai: Yes, clearly, so as I said, the headline numbers especially on the valuations may look expensive, but there are, of course, pockets of opportunities that you continue to see. There was initial period of correction that we have had. So, we have broadly added into some of the pockets where the earnings growth was a bit weaker, especially in the IT because there valuations had become, especially if you were to look at FCF yield and so on and so forth, things were looking a bit better. Also, if you were to look at the whole pharma bucket, there has been lot of news flow around it, again we have used that opportunity to add into some of these names. Same as with the financials. If you look at some of the general insurers, health insurers in the past few quarters, they have not gone anywhere in that sense because there could be one headwind or the other, but broadly if you were to just look at the whole pack, it looks a very fairly underpenetrated segment for country as a whole and long-term growth is not at all at risk. So, not participating in the rally for the past few months or years, we have kind of added into some of these pockets. Pockets we avoid, again, we are a value focused fund, so anything very expensive would be an avoid for us, especially the likes of what we are seeing in the whole cap good space, the defence where things are looking very expensive, although the near-term growth looks positive is what we would typically avoid because of our value focus. Since you said that you have added to some of the pharma counters, of late. Within the earning season, what we are seeing is that the generic companies are highlighting that they are immune to the Trump's executive order. While the CDMO companies with respect to the growth that is a long pending one and the long-term growth outlook is quite robust and then there is API where still that China plus one theme still goes on. Give us some sense within the pharma pack where are you finding opportunities. Christy Mathai: So, mostly our addition is in the generic space, especially the US focused generic, although they have sizable India-centric business as well. See, the point is the executive Trump order pertains to possibly the very high value products, especially coming from innovators or possibly from other developed countries. So, maybe India you would have some exposure, but not much. If some of those pricing are coming down, would there be an impact on generics? We do not really think, but we would have to get into finer nitty-gritties which is not very known at the moment. So, we have by and large found opportunities within the generic space where the valuations were coming down and the past two-three years earnings for a lot of these companies have been driven by fairly benign US pricing environment. It is cyclical to some extent, but the pricing environment in a sense may continue for some time like that, so which would be an impetus and some high value molecules or drugs which have come into the market, some of them are going off, but the point is there is enough and more which the Indian pharma companies through their Para IV filing or first to file there could be an opportunity to replace. So, by and large, we remain constructive on the sector. Again, you have to be very stock specific, so some of them would be trading very expensive, but some of them given the near-term issues might be trading cheap is where we find an opportunity. Just a little while ago you mentioned that cap goods and defence still look a little bit expensive to you. Can I also get your view on the power space. We have been watching out for the earnings, and it has been a mixed set, but the outlook there is very strong across companies. So, what is your take on that space and any names you could help us pick and avoid? Christy Mathai: So, if you were to look at the power sector, again some of these companies have done phenomenally well. We used to own quite a few of them, especially the utility bucket, but we sold out given what we have seen in terms of the rally in the recent past. See, the power sector growth has clearly been ahead of the long-term GDP growth that we have seen and some of them is trickling into whoever lies up ahead in the value chain and there will be more value creation in that bucket as opposed to just the power companies. But again, here the concerns is if you were just to look at the utility space where you get a regulated equity returns, some of these companies are not really priced for that regulated equity returns, which would be in the vicinity of 15-16% give or take. On the other sub-segment where, let us say, you are playing in the value chain within the power sector, again here things are much and beyond because you are looking at maybe two-three years of great earnings or revenue order book growth, but what will happen post that, that is the key you able to generate a secular 18-20% sort of return on equity, that seems to be the concerns especially considering the valuations that we see. So, as I said, we used to own some of these names, but we have kind of sold out in the ensuing rally. Currently, it looks unfavourable in our view. You have told us what is looking actually good to you, but tell us which is the area which is not looking that attractive to you at this point in time. Christy Mathai: If you look at the whole financial space where things have been market linked, could be broking houses, some of the AMCs where the valuations have run up. So, these are the pockets where one has to realise things are a bit cyclical because, for example, if you take a broking house or AMC or anything within that value chain, what you see is, it is linked to the market and there is cyclicality in that. But again our concern here in some of these pockets is, is that cyclicality rightly captured? For example, if you look at a typical AMC, there will be addition in terms of what will be the fresh flows, but there is also an M2M component which kind of helps every year. So, are we baking in great M2M for the next two years? We think not. Chances are there could be correction in that theme. So, all these entities which are market linked to some extent, there could be some bit of correction. In the near term, they are doing well because we have seen a rebound. But we have to think about the next one-year, two-year, three-year what can happen. We would see some drawdowns in some of these pockets, that is our expectation.

Market recovery driven by easing macros and FII inflows, but valuations remain expensive: Christy Mathai
Market recovery driven by easing macros and FII inflows, but valuations remain expensive: Christy Mathai

Time of India

time19-05-2025

  • Business
  • Time of India

Market recovery driven by easing macros and FII inflows, but valuations remain expensive: Christy Mathai

"If you were to look at the earnings trajectory, again first half was pretty bad you have seen sizable earnings cut especially if you were to look at the FY26-27 earnings. But then, this earning season is probably a bit mixed. There are some pockets which have done well, some which has not," says Christy Mathai , Fund Manager-Equity, Quantum AMC. What a move in the markets of late though the news flow was quite volatile. We have been hearing from President Trump . The earning season is in full swing and then, we had the tensions border across. But there is always saying that good price and good news does not come along. Now that we are seeing that the prices are quite looking good, the bulls are seen to be back, especially with their interest in the largecap space and the news is also turning out to be the good, help us understand what is your take on the markets, is the price still good to go ahead and chip in some money? Christy Mathai: So, clearly, as you said the markets have just recovered quite sharply if you were to look at it and possibly some of the easing that we have seen on the macros, especially global macros for that matter, some of the geopolitical tensions easing would have contributed to that and we have seen a fair bit of inflows from the FIIs also, so which has kind of propelled the market to where it is. But see, I would look at from two-three lens. One, of course, if you were to just look at the plain macros, yes, things are improving after sort of not a weak first half FY25, things are just gradually inching up though the GDP estimates has been cut, possibly some bit of easing is happening especially if you look at the RBI actions, there is lot of liquidity infusion, if you were to look at the inflation, things have just kind of come down, that is on the macros. If you were to look at the earnings trajectory, again first half was pretty bad you have seen sizable earnings cut especially if you were to look at the FY26-27 earnings. But then, this earning season is probably a bit mixed. There are some pockets which have done well, some which has not. Our sense is the ask rate in terms of earnings is around 11, 11.5 which is not so demanding. So, the earnings cut further on may not be so steep, perhaps it would have bottomed out in that sense. But the mood point is the valuations . The valuations remain expensive across most of the buckets and that is true more also in the broader end, but if you were to just look out Nifty 50 or BSE 30, the valuations at Nifty at 21.5 is expensive. Live Events So, if you were to just put it all together, yes, we are more constructive with the markets, from the levels six to eight months back, but investors have to possibly be looking at moderate returns, especially in the context of what we have seen three- to five-year returns. Now, the kind of recovery that we have seen in the past few days and also the earnings trajectory, just like you were mentioning, are there any particular pockets where you see value in currently and are there any spaces that one must avoid at this point in time? Christy Mathai: Yes, clearly, so as I said, the headline numbers especially on the valuations may look expensive, but there are, of course, pockets of opportunities that you continue to see. There was initial period of correction that we have had. So, we have broadly added into some of the pockets where the earnings growth was a bit weaker, especially in the IT because there valuations had become, especially if you were to look at FCF yield and so on and so forth, things were looking a bit better. Also, if you were to look at the whole pharma bucket, there has been lot of news flow around it, again we have used that opportunity to add into some of these names. Same as with the financials. If you look at some of the general insurers, health insurers in the past few quarters, they have not gone anywhere in that sense because there could be one headwind or the other, but broadly if you were to just look at the whole pack, it looks a very fairly underpenetrated segment for country as a whole and long-term growth is not at all at risk. So, not participating in the rally for the past few months or years, we have kind of added into some of these pockets. Pockets we avoid, again, we are a value focused fund, so anything very expensive would be an avoid for us, especially the likes of what we are seeing in the whole cap good space, the defence where things are looking very expensive, although the near-term growth looks positive is what we would typically avoid because of our value focus. Since you said that you have added to some of the pharma counters, of late. Within the earning season, what we are seeing is that the generic companies are highlighting that they are immune to the Trump's executive order. While the CDMO companies with respect to the growth that is a long pending one and the long-term growth outlook is quite robust and then there is API where still that China plus one theme still goes on. Give us some sense within the pharma pack where are you finding opportunities. Christy Mathai: So, mostly our addition is in the generic space, especially the US focused generic, although they have sizable India-centric business as well. See, the point is the executive Trump order pertains to possibly the very high value products, especially coming from innovators or possibly from other developed countries. So, maybe India you would have some exposure, but not much. If some of those pricing are coming down, would there be an impact on generics? We do not really think, but we would have to get into finer nitty-gritties which is not very known at the moment. So, we have by and large found opportunities within the generic space where the valuations were coming down and the past two-three years earnings for a lot of these companies have been driven by fairly benign US pricing environment. It is cyclical to some extent, but the pricing environment in a sense may continue for some time like that, so which would be an impetus and some high value molecules or drugs which have come into the market, some of them are going off, but the point is there is enough and more which the Indian pharma companies through their Para IV filing or first to file there could be an opportunity to replace. So, by and large, we remain constructive on the sector. Again, you have to be very stock specific, so some of them would be trading very expensive, but some of them given the near-term issues might be trading cheap is where we find an opportunity. Just a little while ago you mentioned that cap goods and defence still look a little bit expensive to you. Can I also get your view on the power space. We have been watching out for the earnings, and it has been a mixed set, but the outlook there is very strong across companies. So, what is your take on that space and any names you could help us pick and avoid? Christy Mathai: So, if you were to look at the power sector, again some of these companies have done phenomenally well. We used to own quite a few of them, especially the utility bucket, but we sold out given what we have seen in terms of the rally in the recent past. See, the power sector growth has clearly been ahead of the long-term GDP growth that we have seen and some of them is trickling into whoever lies up ahead in the value chain and there will be more value creation in that bucket as opposed to just the power companies. But again, here the concerns is if you were just to look at the utility space where you get a regulated equity returns, some of these companies are not really priced for that regulated equity returns, which would be in the vicinity of 15-16% give or take. On the other sub-segment where, let us say, you are playing in the value chain within the power sector, again here things are much and beyond because you are looking at maybe two-three years of great earnings or revenue order book growth, but what will happen post that, that is the key concern. Are you able to generate a secular 18-20% sort of return on equity, that seems to be the concerns especially considering the valuations that we see. So, as I said, we used to own some of these names, but we have kind of sold out in the ensuing rally. Currently, it looks unfavourable in our view. You have told us what is looking actually good to you, but tell us which is the area which is not looking that attractive to you at this point in time. Christy Mathai: If you look at the whole financial space where things have been market linked, could be broking houses, some of the AMCs where the valuations have run up. So, these are the pockets where one has to realise things are a bit cyclical because, for example, if you take a broking house or AMC or anything within that value chain, what you see is, it is linked to the market and there is cyclicality in that. But again our concern here in some of these pockets is, is that cyclicality rightly captured? For example, if you look at a typical AMC, there will be addition in terms of what will be the fresh flows, but there is also an M2M component which kind of helps every year. So, are we baking in great M2M for the next two years? We think not. Chances are there could be correction in that theme. So, all these entities which are market linked to some extent, there could be some bit of correction. In the near term, they are doing well because we have seen a rebound. But we have to think about the next one-year, two-year, three-year what can happen. We would see some drawdowns in some of these pockets, that is our expectation.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store